Reports of Biochemistry
and Molecular Biology
Thu, Apr 18, 2024
[Archive]
Volume 9, Issue 2 (Vol.9 No.2 Jul 2020)
rbmb.net 2020, 9(2): 230-240 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shaker O, Mahfouz H, Salama A, Medhat E. Long Non-Coding HULC and miRNA-372 as Diagnostic Biomarkers in Hepatocellular Carcinoma patients. rbmb.net 2020; 9 (2) :230-240
URL: http://rbmb.net/article-1-517-en.html
URL: http://rbmb.net/article-1-517-en.html
Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Kafrelsheikh University, Egypt
Abstract: (3187 Views)
Background: We aimed to evaluate the effectiveness of Highly Upregulated in Liver Cancer (HULC) and microRNA-372 (miR-372) as biochemical markers in Hepatocellular carcinoma (HCC) and HCV-infected patients.
Methods: The present study was conducted on 100 Egyptian individuals divided into 3 groups, 40 patients with HCC and HCV infection, 40 patients only HCV-infected, and 20 individuals as normal controls. They were subject to full history taking, full clinical and laboratory examination, and assessment of HULC and miR-372 levels by real-time PCR.
Results: A statistically significant difference was found with p< 0.05 between HCC and each of HCV and control groups as regards HULC level with high mean among HCC followed by HCV patients. Our results also show a statistically significant difference with p< 0.05 between each of HCC and HCV compared to control as regards miR-372 level with low mean among HCC patients.
Conclusions: HULC could be considered as a potential non-invasive marker for detection and early diagnosis of HCC. Also, it may play an important role in the early prophylaxis and control measures to reduce the incidence of HCC. However, miR-372 cannot be considered as a reliable marker as HULC for early detection of HCC especially in HCV patients.
Methods: The present study was conducted on 100 Egyptian individuals divided into 3 groups, 40 patients with HCC and HCV infection, 40 patients only HCV-infected, and 20 individuals as normal controls. They were subject to full history taking, full clinical and laboratory examination, and assessment of HULC and miR-372 levels by real-time PCR.
Results: A statistically significant difference was found with p< 0.05 between HCC and each of HCV and control groups as regards HULC level with high mean among HCC followed by HCV patients. Our results also show a statistically significant difference with p< 0.05 between each of HCC and HCV compared to control as regards miR-372 level with low mean among HCC patients.
Conclusions: HULC could be considered as a potential non-invasive marker for detection and early diagnosis of HCC. Also, it may play an important role in the early prophylaxis and control measures to reduce the incidence of HCC. However, miR-372 cannot be considered as a reliable marker as HULC for early detection of HCC especially in HCV patients.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2020/06/20 | Accepted: 2020/06/23 | Published: 2020/10/7
Received: 2020/06/20 | Accepted: 2020/06/23 | Published: 2020/10/7
References
1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. A Cancer Journal for Clinicians. 2014;64(1):9-29. [DOI:10.3322/caac.21208] [PMID]
2. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: The effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155(4):323-31. [DOI:10.1093/aje/155.4.323] [PMID]
3. Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, et al. Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 2012;491(7424):454-7. [DOI:10.1038/nature11508] [PMID]
4. Panzitt K, Tschernatsch MMO, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a Novel Gene with Striking Up-Regulation in Hepatocellular Carcinoma, as Noncoding RNA. Gastroenterology. 2007;132(1):330-42. [DOI:10.1053/j.gastro.2006.08.026] [PMID]
5. Bartel DP. MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell. 2004;116(2):281-97. [DOI:10.1016/S0092-8674(04)00045-5]
6. Jalali S, Bhartiya D, Lalwani MK, Sivasubbu S, Scaria V. Systematic Transcriptome Wide Analysis of lncRNA-miRNA Interactions. PLoS One. 2013;8(2):e53823. [DOI:10.1371/journal.pone.0053823] [PMID] [PMCID]
7. Chan YH. Biostatistics 102: Quantitative Data - Parametric & Non-parametric Tests. Singapore Med J. 2003;44(8):391-396.
8. Chan YH. Biostatistics 103: Qualitative Data - Tests of Independence. Singapore Med J 2003;44(10):498-503.
9. Chan YH. Biostatistics104: Correlational Analysis. Singapore Med J. 2003;44(12):614-9.
10. Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21(2):105-114. [DOI:10.3350/cmh.2015.21.2.105] [PMID] [PMCID]
11. Huang M De, Chen WM, Qi FZ, Xia R, Sun M, Xu TP, et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2. J Hematol Oncol. 2015;8:50. [DOI:10.1186/s13045-015-0153-1] [PMID] [PMCID]
12. Sun XH, Yang L Bin, Geng XL, Wang R, Zhang ZC. Increased expression of lncRNA HULC indicates a poor prognosis and promotes cell metastasis in osteosarcoma. Int J Clin Exp. Pathol. 2015;8(3):2994-3000.
13. Lu Z, Xiao Z, Liu F, Cui M, Li W, Yang Z, et al. Long non-coding RNA HULC promotes tumor angiogenesis in liver cancer by up-regulating sphingosine kinase 1 (SPHK1). Oncotarget. 2016;7(1):241-54. [DOI:10.18632/oncotarget.6280] [PMID] [PMCID]
14. Garofalo M, Croce CM. microRNAs: Master Regulators as Potential Therapeutics in Cancer. Annu Rev Pharmacol Toxicol. 2011;51:25-43. [DOI:10.1146/annurev-pharmtox-010510-100517] [PMID]
15. Wang J, Liu X, Wu H, Ni P, Gu Z, Qiao Y, et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res. 2010;38(16):5366-83. [DOI:10.1093/nar/gkq285] [PMID] [PMCID]
16. Gamal E-SS, Osama EE agroudy, Seham MS, Hazem HE, Ibrahim AE-M. MicroRNA 122 as adiagnostic biomarker for hepatitis C- related hepatocellular carcinoma. Medical Journal of Viral Hepatitis. 2019;1(1):35-43. [DOI:10.21608/mjvh.2019.59524]
17. Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, et al. Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(5):870-7. [DOI:10.1016/j.cgh.2013.09.053] [PMID] [PMCID]
18. Ataseven H, Bahcecioglu IH, Kuzu N, Yalniz M, Celebi S, Erensoy A, et al. The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm. 2006;2006(4):78380. [DOI:10.1155/MI/2006/78380] [PMID] [PMCID]
19. Axley P, Ahmed Z, Ravi S, Singal AK. Hepatitis C Virus and Hepatocellular Carcinoma: A Narrative Review. J Clin Transl Hepatol. 2018;6(1):79-84. [DOI:10.14218/JCTH.2017.00067] [PMID] [PMCID]
20. Jing CY, Fu YP, Shen HJ, Zheng SS, Lin JJ, Yi Y, et al. Albumin to gamma-glutamyltransferase ratio as a prognostic indicator in intrahepatic cholangiocarcinoma after curative resection. Oncotarget. 2017;8(8):13293-13303. [DOI:10.18632/oncotarget.14530] [PMID] [PMCID]
21. Taverna M, Marie AL, Mira JP, Guidet B. Specific antioxidant properties of human serum albumin. Ann Intensive Care. 2013;3(1):4. [DOI:10.1186/2110-5820-3-4] [PMID] [PMCID]
22. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med. 2004;116 Suppl 7A:11S-26S. [DOI:10.1016/j.amjmed.2003.12.008] [PMID]
23. Finkelmeier F, Bettinger D, Köberle V, Schultheiß M, Zeuzem S, Kronenberger B, et al. Single measurement of hemoglobin predicts outcome of HCC patients. Med Oncol. 2014;31(1):806. [DOI:10.1007/s12032-013-0806-2] [PMID]
24. Fawzy Montaser M, Amin Sakr M, Omar Khalifa M. Alpha-L-fucosidase as a tumour marker of hepatocellular carcinoma. Arab J Gastroenterol. 2012;13(1):9-13. [DOI:10.1016/j.ajg.2012.03.006] [PMID]
25. Li SP, Xu HX, Yu Y, He JD, Wang Z, Xu YJ, et al. LncRNA HULC enhances epithelial-mesenchymal transition to promote tumorigenesis and metastasis of hepatocellular carcinoma via the miR-200a-3p/ZEB1 signaling pathway. Oncotarget. 2016;7(27):42431-42446. [DOI:10.18632/oncotarget.9883] [PMID] [PMCID]
26. Wu G, Liu H, He H, Wang Y, Lu X, Yu Y, et al. miR-372 down-regulates the oncogene ATAD2 to influence hepatocellular carcinoma proliferation and metastasis. BMC Cancer. 2014;14:107. [DOI:10.1186/1471-2407-14-107] [PMID] [PMCID]
27. Wu G, Wang Y, Lu X, He H, Liu H, Meng X, et al. Low miR-372 expression correlates with poor prognosis and tumor metastasis in hepatocellular carcinoma. BMC Cancer. 2015;15(1):182. [DOI:10.1186/s12885-015-1214-0] [PMID] [PMCID]
28. Shrivastava S, Mukherjee A, Ray RB. Hepatitis C virus infection, microRNA and liver disease progression. World J Hepatol. 2013;5(9):479-486. 29. Ramachandran S, Ilias Basha H, Sarma NJ, Lin Y, Crippin JS, Chapman WC, et al. Hepatitis C Virus Induced miR200c Down Modulates FAP-1, a Negative Regulator of Src Signaling and Promotes Hepatic Fibrosis. PLoS One. 2013;8(8):e70744. [DOI:10.1371/journal.pone.0070744] [PMID] [PMCID]
29. Liu X, Wang T, Wakita T, Yang W. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology. 2010;398(1):57-67. [DOI:10.1016/j.virol.2009.11.036] [PMID]
30. Gu H, Guo X, Zou L, Zhu H, Zhang J. Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma. Mol Cell Biochem. 2013;375(1-2):23-30. [DOI:10.1007/s11010-012-1521-6]
31. Zhu Y, Chen X, Zheng C, Rao X, Peng X. Down-regulation of LncRNA UCA1 alleviates liver injury in rats with liver cirrhosis. Int J Clin Exp Pathol. 2019;12(2):455-465.
32. Yang Z, Lu Y, Xu Q, Tang B, Park C-K, Chen X. HULC and H19 Played Different Roles in Overall and Disease-Free Survival from Hepatocellular Carcinoma after Curative Hepatectomy: A Preliminary Analysis from Gene Expression Omnibus. Dis Markers. 2015;2015:191029. [DOI:10.1155/2015/191029] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
